Our data supports that polyI:C (its analogue, Hiltonol) is a promising adjuvant in combination with anti-IL6 antibody and/or JAK2/STAT3 inhibitors, for lung cancer immunotherapy. The gene discussed is JAK2; the disease is lung carcinoma.